NK t-MN present better prognosis, lower frequency of TP53 mutations and higher frequency of TET2, NPM1, ASXL1, SRSF2, RUNX1, KRAS, FLT3 and STAG2 mutations [29–31]. This evidence concerns the gene KRAS and therapy-related myeloid neoplasm.